Definitive Contract 75F40123C00213

This is a $964,769 firm-fixed price contract awarded by the Food and Drug Administration (FDA) to Rutgers, The State University. The contract is for research and development on the role of excipients and excipient substitution in topical semi-solid formulations and their effect on product performance and quality. This work falls under the FDA's Broad Agency Announcement (BAA) focused on advancing regulatory science and innovation across areas such as modernizing product development and evaluation. Rutgers, a major public research university, will leverage its expertise and facilities to deliver technical solutions in support of the FDA's mission. The contract has a period of performance ending on September 29, 2027 and was not set aside for any particular business type.